Genolife

Can a liquid biopsy replace a tissue biopsy? A perspective from lung cancer
Over the past few decades, the concept of precision medicine has drastically transformed the field of medical oncology; the implementation of patient-tailored therapies has improved significantly. Liquid Biopsy It is a revolutionary technique that opens up previously unexpected possibilities. It consists of the detection and isolation of circulating tumor cells, circulating tumor DNA, and exosomes, as a source of genomic information in cancer patients. The identification of predictive biomarkers Tumor tissue analysis is now essential for optimal patient care, but it faces several biological and technological challenges. A recent study of multiple samples from lung cancer patients demonstrated that there is intratumoral heterogeneity between different regions within the same tumor (spatial heterogeneity), as well as between the primary tumor and local or distant recurrences in the same patient (temporal heterogeneity). In addition, other studies have characterized the dynamic changes in tumor characteristics over the course of the disease, and these changes have affected the treatment resistance. Therefore, inter- and intratumoral heterogeneity poses a fundamental challenge for guiding clinical decision-making in pulmonary oncology, since the Tissue biopsies can be inaccurate to capture the complete genomic profile of a cancer patient.

On the other hand, the comprehensive genomic information Tumor resection is often limited by its accessibility, due to the rate of clinical complications associated with the invasive procedures necessary for obtaining tissue samples at the time of the initial diagnosis, as well as during the course of treatment for the disease.
In addition to this, another major barrier to biomarker testing is the availability of an adequate amount of tissue, due to the multiple tests performed on a single sample and the reduced amount of tissue submitted per patient. Typically, In less than 80% of patients with lung cancer in an advanced stage, a small tissue biopsy can be taken, which limits the ability to perform additional tests; the remaining patients do not have tissue accessible for a biopsy. Even when tissue can be collected, preservation methods, such as formalin fixation, may result in high levels of changes in genetic material for molecular testing.

Finally, the tissue biopsies also increase the cost of patient care and the time it takes to get results It may sometimes take longer than the doctor expects to treat the patient. In light of these restrictions on the use of tissue biopsies, New approaches to studying tumor genetics and tumor dynamics have emerged.
Currently, a Liquid biopsy provides an alternative type of sample in routine clinical practice when a tumor sample is unavailable, unsuitable, or difficult to obtain. Furthermore, sampling is less invasive for the genomic characterization of ctDNA or CTCs and enables repeatable evaluation throughout the course of therapy and early identification.

Important Key Points to Consider
  • The lack of representation of a tumor's heterogeneity and the limited availability of samples mean that the Tissue biopsies have limited value to assess tumor dynamics in advanced stages of the disease.
  • Long delays between sample collection and the receipt of clinical results can lead to a altered genetic composition of the tumor.
  • Circulating free DNA can be extracted from blood (liquid biopsy) and analyzed for tumor-specific abnormalities to provide a a more comprehensive genetic picture in a patient.
  • Monitoring tumor-associated genetic aberrations via liquid biopsy can be used to assess the presence of residual disease, recurrence, relapse, and resistance.
  • A liquid biopsy can be used to detect the presence of cancer cells among 5 and 10 months earlier than conventional methods.
Important Clinical Benefits of Liquid Biopsy
Diagnosis
Early detection
Complete Tumor Profile
Identification of Multiple Tumor Sites
Monitoring of Residual Diseases
Diagnosis of Relapse
Forecast
Identification of Genetic Markers for Targeted Therapies
Early Assessment of Therapeutic Efficacy
Post-Surgery Follow-Up
Monitoring the emergence of treatment resistance (emergence
(such as genetic mutations) in real time.
Forecast
Identifying the Risk of Relapse
Early Assessment of Cancer Progression

Are you interested in any of our services?

Schedule an appointment with our specialists.